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PPAR-γ agonists have been associated with heart failure (HF) in diabetic patients. These incidences have been reported mostly
in patient populations who were at high risk for HF or had pre-existing impaired cardiovascular function. However, whether
there are similar eﬀects of these agents in subjects with no or reduced cardiovascular pathophysiology is not clear. In this study,
the eﬀects of chronic treatment with PD168, a potent peroxisome proliferator activated receptor (PPAR) subtype-γ agonist with
weak activity at PPAR-α, and rosiglitazone (RGZ), a less potent PPAR-γ agonist with no PPAR-α activity, were evaluated on the
cardiovascular-renal system in healthy male Sprague-Dawley (SD) rats by serial echocardiography and radiotelemetry. Rats were
treated with vehicle (VEH), PD168, @ 10 or 50mg/kg·bw/day (PD-10 or PD-50, resp.) or RGZ @ 180mg/kg·bw/day for 28 days
(n = 10/group). Relative to VEH, RGZ, and both doses of PD168 resulted in a signiﬁcant fall in blood pressure. Furthermore, RGZ
and PD168 increased plasma volume (% increase from baseline) 18%, 22%, and 48% for RGZ, PD-10, and PD-50, respectively.
PD168 and RGZ signiﬁcantly increased urinary aldosterone excretion and heart-to-body weight ratio relative to VEH. In addition,
PD168 signiﬁcantly decreased (10–16%) cardiac ejection fraction (EF) and increased left ventricular area (LVA) in systole (s) and
diastole (d) in PD-10 and -50 rats. RGZ signiﬁcantly increased LVAd; however, it did not aﬀect EF relative to VEH. In conclusion,
chronic PPAR-γ therapy may predispose the cardiorenal system to a potential sequela of structural and/or functional changes that
may be deleterious with regard to morbidity and mortality.
Copyright © 2009 Eileen R. Blasi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are part
of the nuclear receptor superfamily that includes at least
three members, that is, alpha, beta, and gamma encoded by
distinct genes. They have principal roles in metabolism, for
example, tissue energy storage and utilization. PPAR alpha is
expressed in tissues like brown adipose tissue, liver, kidney,
intestine, heart, and skeletal muscle, with signiﬁcant fatty
acidandcholesterolcatabolism.Itisakeyregulatorofenergy
homeostasis and plays a major role in lipid metabolism
and glucogenesis. PPAR-γ on the other hand is present
at high levels in adipose tissue, gut, brain, vascular cells,
immune cells, and retina. PPAR-γ plays a role in adipocyte
diﬀerentiation, glucose metabolism, and lipid homeostasis,
and participates in monocyte/macrophage diﬀerentiation.
In the heart, the expression of PPAR-γ is relatively lower
than PPAR-α [1, 2]. However, despite its lower expression, a
prominent role for PPAR-γ in cardiac function, particularly
in the left ventricle has been suggested [3]. Murine models
have been used to determine the direct eﬀects of PPAR
receptors in the heart [2, 4]. Studies using cardiac-speciﬁc
deletion revealed that loss of PPAR-γ from the heart resulted
in mild cardiac hypertrophy [2]. However, in the same study,
it was shown that treatment with rosiglitazone, a commonly
utilizedPPAR-γ agonist,alsoresultedincardiachypertrophy,
in both wild type and cardiac-speciﬁc PPAR-γ knockout
mice. This suggested that the presence of PPAR-γ may be2 PPAR Research
essential for normal cardiac development, but that treatment
with exogenous PPAR-γ agonists might also be detrimental
[2].
PPAR-γ agonists are widely used for the treatment of
type2 diabetes. These agents alone or in combination with
PPAR-α agonists lead to adipogenesis, increased energy stor-
age,andreducedinsulin-resistanceandhyperglycemia[5–9].
In addition, these agents have been shown to reduce inﬂam-
mation and atherosclerosis and thereby prove beneﬁcial for
the treatment of cardiovascular diseases (CVD) [10–12].
However, treatment with PPAR-γ agonists are commonly
associated with unwanted side eﬀects including edema and
weightgain.Recently,treatmentwithrosiglitazone(Avandia)
has been associated with increased risk of myocardial infarc-
tionandpossiblydeathfromcardiovascularcausesinspeciﬁc
patient populations, that is, those with underlying cardio-
renal diseases, however these eﬀects are still controversial
[13–16]. Despite these serious side eﬀects, these drugs are
still one of the most eﬀective treatments for type 2 diabetes,
and have additional anti-inﬂammatory actions that are of
beneﬁt. However, some studies suggest detrimental side
eﬀects may outweigh the beneﬁts of currently available
PPAR-γ agonists, and further reﬁnement of the chemical
nature of these drugs, and possibly combination with
diuretics is needed [17, 18].
Type 2 diabetes is commonly associated with congestive
heart failure (CHF), impaired cardiac function and reduced
cardiac reserve. This association is especially strong in the
elderly or in later stages of diabetes [19, 20]. Treatment
with PPAR-γ agonists has been shown to further exacerbate
cardiac dysfunction and induce cardiac hypertrophy in these
patients [10, 13, 14]. So far, these eﬀects of PPAR-γ agonists
have been demonstrated mainly in animal models of disease
or in subjects at high-risk for myocardial infarction. High-
risk components include impaired coronary ﬂow reserve,
even in the absence of obstructive epicardial coronary dis-
ease,myocardialﬁbrosis,andmaladaptivemyocardialenergy
metabolism. However, it is unclear whether PPAR-γ agonists
aﬀect the healthy heart. Furthermore, PPAR-γ therapy is
more commonly associated with edema, even to a greater
extent than with CHF. Thus, it is possible that PPAR-γ
agonists may precipitate symptoms of CHF through plasma
volume expansion. Therefore, in this report the eﬀects of
chronicPPAR-γ agonisttreatmentwereexaminedinnormal
healthy young, male Sprague Dawley (SD) rats, with no risk
factors for CHF. Previously, it has been shown that SD rats
develop edema and reduced BP with short-term PPAR-γ
treatment [21].
In the present study, the dose-dependent eﬀects of
chronic PPAR-γ agonist administration on blood pressure
and cardiac structure and function in relation to the
development of edema was evaluated in healthy SD rats. In
this study we used two diﬀerent agonists of PPAR-γ with
diﬀerent potencies for PPAR-γ; 1) PD-0344168 (PD168),
which is a coagonist that exhibits much stronger aﬃnity
for PPAR-γ with an EC50 of 5nM for PPAR-γ while also
displaying very weak alpha activity at 70nM [21], and 2)
Rosiglitazone (RGZ)whichhasanEC50 of 200nM for PPAR-
γ and inactivity at PPAR-α [22]. Rats were treated for 28
d a y swi t he i t h e r1 0o r5 0m g / k gP D 1 6 8o r8 0m g / k gR G Za n d
blood pressure as well as cardiac structure and function were
evaluated over the time course of treatment.
2.MaterialandMethods
2.1. Animals and Experimental Design, (Figure 1). Forty
male SD rats of ∼275g were obtained from Charles River
Laboratories (Wilmington, Mass, USA). Animals were main-
tained at all times under protocols approved by the Pﬁzer
(International Animal Care and Use Committee) IACUC.
Rats were randomly assigned to four treatment groups
(n = 10/group): vehicle, PD-10 (10mg/kg·bw/d), PD-50
(50 mg/kg·bw/d), or rosiglitazone (RGZ, 80 mg/kg·bw/d).
Baseline echocardiographic examinations were performed.
The day following baseline echocardiography, telemetry
devices were surgically implanted in the rats for continuous
blood pressure monitoring (20-second reading, once every
15 minutes, 24 hours a day). Animals were dosed by gavage
one time per day for 28 days with either vehicle (0.5%
methylcellulose) or one of the two doses of PD168 in
0.5% methylcellulose. At the end of the study, animals
were euthanized by conscious decapitation. For pathological
examination, hearts were quickly excised, rinsed in sterile
saline, blotted dry and weighed. Hearts were placed in 10%
neutral buﬀered formalin (NBF).
2.2. Clinical Chemistry. Blood was collected into vacutainer
tubes containing either K+-EDTA or heparin, centrifuged at
3000rpm, and plasma collected and stored at −80◦C until
further analysis. Glucose and electrolytes were analyzed by
routine clinical chemistry protocols on a Hitachi analyzer;
hematocrit and hemoglobin were determined on the Advia
120 hematology analyzer (Bayer), and adiponectin was
assayed by an enzyme-linked immunoassay (ELISA, mouse-
rat adiponectin kit, B-Bridge International, Mountainview,
Calif,USA).Twenty-four-hoururinewascollectedattheend
ofthestudytomeasureurinaryexcretionofelectrolytes(Na+
and K+) and total protein (Hitachi clinical chemistry ana-
lyzer). Aldosterone was assayed using standard procedures
via radioimmunoassay (RIA) using 125I-labeled aldosterone
(Diagnostic Products Corporation, Los Angles, Calif, USA).
2.3. Echocardiography. Serial echocardiographic examina-
tions were performed on day 1, 3, 5, 7, 14, 21, and 28 of
dosing using the Agilent SONOS 5500 echocardiographic
system equipped with a 15-MHz linear-array transducer
(Agilent, Andover). Images were captured from rats lightly
anesthetized with 1-2% isoﬂurane (AErrane; Baxter, Inc.,
Deerﬁeld, Mass, USA) lying on their left side with the
transducer placed on the left hemithorax. Two-dimensional
parasternal long and short-axis images of the left ventricle
as well as two-dimensional targeted M-mode tracings were
recorded from the parasternal short-axis view at the level
of the papillary muscles at a sweep speed of 150mm/s.
Doppler ﬂow velocities were taken at the level of the mitral
valve in the apical 4-chamber view with the Doppler probe
placed at the edge of the mitral leaﬂets. All measurementsPPAR Research 3
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Figure 1: Schematic diagram of study design; echocardiography, echo.
were performed according to the recommendations of
the American Society for Echocardiography leading-edge
methodfromthreeconsecutivecardiaccycles.Measurements
and calculations used were as follows: End diastolic (EDV)
and systolic (ESV) volumes were calculated from LV systolic
(LVAs) and diastolic (LVAd) areas. Ejection fraction (EF)
was calculated from systolic and diastolic volumes with the
following formula: EF = (EDV − ESV)/EDV × 100%.
2.4.BloodPressure(BP). Allanimalswereinstrumentedwith
PA-C40 radiotelemetry units (Data Sciences Inc., St. Paul,
Minn,USA) forconscious,unrestrictedBPmeasurementsas
previously described [21]. Brieﬂy, animals were anesthetized
with 3% isoﬂurane and a 5-cm midline incision was made
through the skin and muscle layer of the abdominal wall
exposing the peritoneal cavity. A 1.5-cm segment between
the renal arteries and the bifurcation of the iliac arteries
was exposed and the aorta was cannulated to insert the
indwelling radiotelemetry probe-ﬂow catheter. The trans-
mitter was sewn into the muscle layer and the abdominal
wall was closed. Postoperative care included treatment
with 0.1mg/kg, s.c. buphrenorphine and monitoring of the
animals, which were placed on thermogenic heating pads
during recovery from anesthesia until sternal recumbency
and alertness were obtained.
2.5. Statistical Analysis. Data were presented as mean ±
SEM. The means for VEH, PD-10, and PD-50 groups were
compared using one-way analysis of variance (ANOVA)
followed by Holm-Sidak multiple comparisons test, if sig-
niﬁcant. Values of p<0.05 were used to show signiﬁcance
for the planned comparisons between the means. The
means for VEH and RGZ groups were compared separately
using unpaired t-test, values of p<0.05 were considered
signiﬁcant.
3. Results
3.1. Eﬀect of PD168, a PPAR α/γ Agonist
3.1.1. Serum Glucose and Plasma Adiponectin Levels with
Chronic PD168 Treatment in Normal Rats. After 4 weeks
of treatment, plasma adiponectin levels were signiﬁcantly
higherinPD168-treatedgroupsrelativetothevehicle-treated
group; 3.5 and 4.3 fold, for the 10mg/kg and 50mg/kg
treatment groups, respectively (Figure 2(a)). Consistent with
these changes, the serum glucose levels, under a fed state,
were signiﬁcantly lower (25% and 31% relative to vehicle for
the 10 and 50mg/kg treatment groups, resp.) after 4 weeks of
treatments (Figure 2(b)).
3.1.2. Edema in Rats Treated with Chronic PD168. In all
the blood collections after the start of treatments, that is,
day 7, 14, 21, and 28, the hematocrit (HCT, % packed red
blood cells), as well as the levels of hemoglobin (HBG) in
the plasma of PD168-treated groups were signiﬁcantly lower
relative to the vehicle group (Figure 3(a)). At the end of the
study,thetotalreductionsinHCTwere6%,10%,and21%in
vehicle,PD-10,andPD-50groups,respectively.Similarly,the
total reductions in plasma HBG were 8%, 11%, and 20% in
vehicle,PD-10andPD-50groups,respectively.Thechangein
plasmavolume(%PV),ascalculatedusing%HCTandHBG,
was signiﬁcantly higher in the PD-50 group and trended to
behigherinPD-10group,relativetovehicle-treatedrats.The
%PVs were 7.9 ± 3.4, 22.1 ± 3.5, and 48.5 ± 8.2 for vehicle,
PD-10, and PD-50, respectively, (Figure 3(b)).
In addition to HCT and HBG levels, gross observa-
tional signs of subcutaneous edema (swollen face, chest,
extremities) coupled with interstitial ﬂuid measured (from
the thoracic cavity) were found in the PD168-treated rats.
Four out of ten rats in PD 168-10 groups (40%) and seven
out of ten rats in PD-50 group (70%) exhibited these signs.
No such signs were observed in the vehicle-treated group4 PPAR Research
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Figure 2: Plasma adiponectin (a) and serum glucose (b) levels
in normal male SD rats chronically treated with vehicle (VEH),
PD168 at a dose of 10 (PD-10) or 50mg/kg·body weight (PD-50),
(n = 10/treatment group). Means were compared using one-way
ANOVA followed by the Holm-Sidak multiple comparisons test.
Data were represented as means ± SEM. Bars designated with “A”
are signiﬁcantly greater in value than bars designated with “B” and
so forth (by Holm-Sidak). p<0.05 was considered signiﬁcant.
(0%). Thoracic ﬂuid retention in the PD-10 group ranged
in volume from 0.2–0.5 ml, and in PD-50 group the ﬂuid
volume ranged from 0.6–1+ ml. Additionally, body weight
gains were 59% and 62% respectively, for the PD-10 and PD-
50 groups relative to 50% for the vehicle-treated group at the
end of 28 days of treatment. Taken together, along with HCT
and HBG values, edema and plasma volume expansion were
evident with treatment.
3.1.3. Evidence for an Activated Aldosterone Activity in Rats
Treated with Chronic PD168. Urine was collected for 24
hours before the end of the study to measure urinary
excretion of sodium, potassium, and aldosterone. After 4
weeks of treatment, the urinary Na+/K+ ratio was found to
be signiﬁcantly decreased in PD168-treated rats (both 10
and 50mg/kg) relative to vehicle-treated rats (Figure 4(a)).
In addition, urinary aldosterone excretion was signiﬁcantly
increased by PD168 treatment (Figure 4(b)). Changes in
these parameters indicate activation of aldosterone synthesis
or reduced degradation or in PD168-treated rats relative to
vehicle.
3.1.4. Cardiac-Hypertrophy by PD168 Administration.
Chronic PD168 treatment resulted in eccentric hypertrophy
as evidenced by signiﬁcantly increased absolute heart
weight (Figure 5(a)). In addition, heart-to-body-weight
ratios were also signiﬁcantly increased by PD168 treatment
(Figure 5(b)). Heart-to-body-weight ratios were 23.4% and
30.4% higher in the PD-10 and −50 groups, as compared to
vehicle. However, compound-related morphologic changes
such as signs of cardiac lesions, necrosis or ﬁbrosis, were not
observed in this study.
3.1.5. Left Ventricular Dysfunction by Chronic PD168 Treat-
ment. Echocardiography was performed a day before the
start of the treatment (day 0) then every other day for
one week (days 1, 3, 5, and 7); and thereafter, once a
week until the end of the experiment (days 14, 21, and
28). Echocardiographic analysis revealed signiﬁcant systolic
and diastolic dysfunction as evidenced by an increase in
the LVA in systole and diastole (Figure 6(a)). In systole,
PD-10 and −50 resulted in a 53% and 80% increase in
area, respectively, from baseline after 4 weeks. In diastole,
PD-10 and −50 resulted in an 18%, and 29% increase
respectively, from baseline after 4 weeks. Figure 6(b) shows a
signiﬁcant increase in the left ventricular internal dimension
(LVID) in PD168-treated groups over time, in both diastole
and systole. Furthermore, ejection fraction was signiﬁcantly
decreased in both doses after day 14 of PD168 treatment
(Figure 6(c)) .B yt h ee n do f4w e e k so ft r e a t m e n t ,E Fw a s
decreased from baseline by 10% and 16% in PD-10 and
−50, respectively. However, EF in the vehicle-treated group
remained unchanged over the 4 week study.
3.1.6. Eﬀect of Chronic PD168 Treatment on BP and Total
Protein Excretion. BP and heart rate (HR) were measured
throughout the study using radiotelemetry. Systolic BP
(SBP) was signiﬁcantly reduced by both doses of PD168
(Figure 7(a)). At the lower dose (PD-10), SBP was signif-
icantly reduced relative to the vehicle group through day
17 of the treatment; however, it rebounded on day 18 and
was no longer signiﬁcantly diﬀerent from vehicle for the
remainderofthestudy.However,atthehigherdose(PD-50),
SBP remained signiﬁcantly reduced by about 11% relative to
the vehicle group, throughout the course of the 28 days of
treatment. Diastolic BP showed the same trend as SBP (data
notshown).TherewasasigniﬁcantelevationinHRwithPD-
50 in the ﬁrst 5 days, likely in response to the fall in BP. Total
urinary protein excretion was measured to assess integrity of
the glomerulus and associated ﬁltration membranes. Protein
excretion was found to be signiﬁcantly lower in both PD168-
treated groups related to vehicle (Figure 7(b)).
3.2. Eﬀects of Rosiglitazone, a PPARγ Agonist
3.2.1. Plasma Adiponectin and Serum Glucose Levels with
Chronic Rosiglitazone Treatment in Normal Rats. RGZ treat-
ment signiﬁcantly increased plasma adiponectin levels rela-
tive to the vehicle-treated group (Figure 8(a))a f t e r4w e e k s .PPAR Research 5
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Figure 3: Hematocrit and hemoglobin levels in PD168-treated rats. (a) Percentage hematocrit (HCT) and hemoglobin levels and
(b) percentage change in plasma volume, estimated indirectly by calculating percent change using baseline and ﬁnal hemoglobin and
hematocrit values in normal male SD rats chronically treated with vehicle (VEH), PD168 at the dose of 10mg/kg·body weight (PD-10)
or 50mg/kg·body weight (PD-50), (n = 10/treatment group). Means were compared using one-way ANOVA followed by the Holm-Sidak
multiple comparisons test. Data are represented as means ± SEM. Points designated with “A” are signiﬁcantly greater in value than those
designated with “B” (by Holm-Sidak). p<0.05 was considered signiﬁcant.
Consistently, serum glucose levels were signiﬁcantly lower in
RGZ treated groups relative to vehicle (Figure 8(b)).
3.2.2. Urinary Aldosterone Excretion, Plasma Volume and
Systolic Blood Pressure with Chronic Rosiglitazone Treatment
in Normal Rats. Rats treated with RGZ had signiﬁcantly
increased urinary aldosterone levels relative to vehicle group
(Figure 8(c)) in their 24 hour urine samples collected
towards the end of the study.
Percentage change in plasma volume (%PV) was calcu-
lated using %HCT and HBG levels, measured in the blood
collected at baseline and at the end of the study. Percentage
PVwastrending higherinRGZtreatedratsrelativetovehicle
(Figure 8(d); not signiﬁcant). Furthermore, RGZ treated
rats had a signiﬁcant fall in systolic blood pressure (SBP)
at treatment days 4 to 6 relative to vehicle (Figure 8(e)).
After day 6, the SBP rebounded back and was no longer
signiﬁcantly diﬀerent from vehicle for the remainder of the
study.
3.2.3. Eﬀect of Chronic Rosiglitazone on Cardiac Structure
and Function. RGZ treatment resulted in cardiac hyper-
trophy as indicated by a signiﬁcant increase in absolute
heart weight as well as heart-to-body-weight ratio relative
to the vehicle-treated group (Figure 9(a)). Furthermore,
echocardiographic analysis revealed that RGZ resulted in
a signiﬁcant increase (21.5% from baseline) in the left
ventricular area (LVA) in diastole relative to vehicle group6 PPAR Research
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Figure 4: Aldosterone activity and excretion. (a) urinary sodium
to potassium ratio (Na:K) and (b) aldosterone excretion in normal
male SD rats chronically treated with vehicle (VEH), PD168 at
the dose of 10mg/kg·body weight (PD-10) or with PD168 at the
dose of 50mg/kg·body weight (PD-50), (n = 10/treatment group).
Means were compared using one-way ANOVA followed by Holm-
Sidak test. Data are represented as means ± SEM. Diﬀerent letters
represent signiﬁcant diﬀerences between the groups with “A” being
highest mean and so forth (p< 0.05 was considered signiﬁcant).
after 4 weeks (Figure 9(b)). For LVA in systole there was a
trend for an increase relative to vehicle group (9.8% from
baseline), however, it was not signiﬁcant. Furthermore, RGZ
did not have any signiﬁcant eﬀect on the ejection fraction
relative to the vehicle group (Figure 9(c)).
4. Discussion
The following study demonstrated the eﬀects of chronic
treatment with PD168 or RGZ on the hearts of healthy,
young SD rats. PD168 has highly potent PPAR-γ activity
(5nM) with weaker PPAR-α activity (70nM). RGZ, on the
other hand has an EC50 of 200nM for PPAR-γ and inactivity
at PPAR-α. Chronic treatment with PD168 for 28 days
resulted in reduced blood pressure and a fall in hematocrit
e a r l yo nf o l l o w e db yc a r d i a ch y p e r t r o p h y ,e x p a n s i o no f
the left ventricular area, and reduced ejection fraction. In
addition, chronic PD168 treatment resulted in increased
urinary aldosterone. The above parameters were modiﬁed,
in general, in a dose-responsive fashion. The RGZ treatment
for 28 days had a similar eﬀect on aldosterone excretion and
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Figure 5: Cardiac hypertrophy in PD168 rats (a) absolute heart
weight and (b) heart-to-body-weight ratio in normal male SD rats
chronicallytreatedwithPD168atthedoseof10mg/kg·bodyweight
(PD-10) or 50mg/kg·body weight (PD-50) relative to vehicle
(VEH), (n = 10/treatment group). Means were compared using
one-wayANOVAfollowedbyHolm-Sidaktest.Dataarerepresented
as means ± SEM. Diﬀerent letters represent signiﬁcant diﬀerences
between the groups with “A” being highest mean and so forth (p<
0.05 was considered signiﬁcant).
cardiac structure; however it did not increase plasma volume
or reduce ejection fraction or blood pressure to the same
extent of PD168. Overall, RGZ at this dose appeared to have
less detrimental eﬀects than PD168 which we believe could
be due to the diﬀerence in the potency of the two drugs used
at these doses.
Plasma concentrations of PD168 were determined using
a sensitive, drug-speciﬁc, HPLC-tandem mass spectrometry
assay. The average steady state concentration was 460
ng/mL and 3300ng/mL for PD168-10mg and PD168-50mg,
respectively. The dose selection rationale for this study was
aimed to achieve doses ranging from 0.5–10+ fold over the
predicted human eﬃcacious concentration (C-eﬀ)i nZ u c k e rPPAR Research 7
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Figure 6: Left ventricular expansion and ejection fraction in PD168 treated rats. (a) Left ventricular area (LVA) in systole and diastole; (b)
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Figure 7: (a) Systolic blood pressure and (b) Urinary protein
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50mg/kg·body weight (PD-50), (n = 10/treatment group). Means
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highest mean and “AB” not diﬀerent from “A” or “B” and so forth
(p<0.05 was considered signiﬁcant).
diabetic fatty rats that lowered glucose to below the target
concentration of 200mg/dL. The values above were from
approximately 1 and 10-fold over the predicted human C-
eﬀ of 465 ng/mL. The pharmacokinetic assay measures total
drug concentration over time, and at the doses evaluated in
the study and the margins achieved we would consider this
to be within the “proposed” clinical range (although this
compound was discontinued and never tested in humans).
As such, we would speculate that achieved highly potent
PPAR-γ activity with very low alpha activity. However, at the
higher dose we cannot rule out the potential eﬀect of some
alpha activity as it could not be directly measured.
4.1. Chronic PD168 Treatment Induced a Fall in Blood
Pressure and Plasma Volume Expansion in Normal Rats.
In agreement with ﬁndings from our previous study with
shorter term PD-168 treatment [21], in the present study a
signiﬁcant fall in hematocrit (%) with PD168 (Figure 3(a))
was demonstrated. In addition, visible signs of subcutaneous
edema coupled with interstitial ﬂuid accumulation, weight
gain and increases in plasma volume, measures of edema
and volume retention, were found with PD168 treatment.
TherearenumeroustheoriesregardinghowPPAR-γ agonists
induce edema. One hypothesis is that this class of agents
increase capillary permeability. In this regard, RGZ has been
shown to modulate vascular permeability in a tissue-speciﬁc
manner [18, 23–26]. Furthermore, the fall in blood pressure
induced by PD-168 may also be a contributing factor to the
edema since activation of aldosterone activity may facilitate
increased salt and water retention through positive feedback
mechanisms. In addition, the decrease in blood pressure
preceded the edema after PD168 treatment. Our earlier
studies also supported this ﬁnding in that a signiﬁcant fall
in blood pressure from 12 hours postdose was followed
by a signiﬁcant fall in hematocrit, initiated from day 3 of
treatment [21].
An additional contributing mechanism for the edema
may be PPAR-γ activation directly modulating distal sodium
transport and inducing water retention. In this regard, it
has been shown that thiazolidinedione-induced edema was
partially blocked by antagonizing ENaC [27]. Mice with tar-
geted knockout of the PPAR-γ receptor in the collecting duct
(CD) of the kidney had less severe thiazolidinedione-(TZD)
induced edema and also TZDs induced NaCl reabsorption
[28]. Thus increased sodium reabsorption by chronic PD168
treatment found in the present study could be a direct
eﬀect of PPAR-γ on the renal distal tubule in these rats.
Previously it has been shown that short-term rosiglitazone
treatment reduces BP and increases sodium retention in
healthy rats [29]. Furthermore, results from our previous
study with shorter-term PD168 treatment have suggested
initial activating changes in distal sodium and water trans-
porterprotein,ENaCandAQP-2proteinexpressionfollowed
by their compensatory downregulation by day 5 [21]. As
such, there is a possibility that PD168 increases sodium
reabsorption by having a direct action on the renal salt and
water proteins. However, whether PPAR-γ agonists directly
increases the activity of ENaC is still controversial. Hong
et al. [30] have found increased cell surface expression of
ENaC by PPAR-γagonists. While, Nofziger et al. [31] did not
report any increase in PPAR-γ-inducedNa+inﬂuxviaENaC.
Thus further studies are warranted to further elucidate the
mechanism for TZD-associated edema.
Regarding the mechanism for the fall in blood pressure,
PPAR-γ agonistsmayhaveadirectvasodilatory actiononthe
vasculature. In agreement with this hypothesis, rosiglitazone
has been shown to cause vasorelaxation [32]. Speciﬁcally,
Eto and colleagues have demonstrated that rosiglitazone
causes attenuation of inward calcium currents and enhanced
calcium-activated potassium currents in isolated vascular
smooth muscle cells [33]. Modulation of calcium and potas-
siummaybeapossiblemechanismforrosiglitazone-induced
vasorelaxation since attenuated inward calcium currents and
enhanced calcium-activated potassium currents would causePPAR Research 9
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cellular hyperpolarization and, therefore, relaxation of the
vessel.
Previously, we reported that short term (1–5 days) treat-
mentwithPD168(10mg/kg)ledtoasigniﬁcantfallinhema-
tocritandreductioninbloodpressure.Inthepresentchronic
study, 28 days of repeat dosing showed similar eﬀects.
However, there was an attempt at physiological adaptation
withregardtothefallinbloodpressurewhichwasattenuated
after day 18th of the low-dose treatment (Figure 7(a)). These
results may indicate some sort of compensatory mechanism
in play. Furthermore, this compensation appears to be lost
with the higher dose of this drug. Increased aldosterone
in these rats may be playing a role in this inability to
compensate.
With regard to kidney, the PD-168-induced depressor
eﬀect may have a protective eﬀect as suggested by signif-
icantly lower total protein excretion in the PD168-treated
rats. This is in agreement with other studies which have
demonstrated reduced urinary albumin excretion and reno-
protection by thiazolidinediones [34–36]. The mechanisms
f o rr e d u c e dp r o t e i ne x c r e t i o na n dr e n o p r o t e c t i o nm a yb e
direct or indirect, due to the lowering of glucose levels or
decreased blood pressure [35, 37–41].
4.2. Cardiac Hypertrophy and Reduced Cardiac Function.
Cardiac hypertrophy in response to PPAR-γ exposure might
be the result of direct or indirect actions of these agents.
With regard to indirect actions, it is plausible that the cardiac
hypertrophy found in our rats might reasonably be the result
of volume overload [42, 43]. A similar observation was made
by Arakawa and colleagues in diabetic SD rats treated with
T-174, a drug with potent PPAR-γagonistic activity and oral
antidiabetic action [44]. The authors suggested that plasma-
volume expansion led to cardiac volume overload, which
then contributed to hypertrophy of the heart. This hypoth-
esis is also supported by an in vitro study in cardiomyocytes
by Sandra and colleagues [45] which demonstrated that
cardiac hypertrophy associated with the treatment of PPAR-
γ agonists was not due to the direct cardiac eﬀects of PPAR
agonists, for example, activation of cardiac PPAR-γ receptors
orincreasedmyocardialinsulinsensitivity.Thusinductionof
cardiac hypertrophy could be an indirect rather than direct
cardiomyocyte-speciﬁc eﬀect of these agents. In this regard,
rosiglitazone has been shown to induce cardiac hypertro-
phy in mice with cardiac-speciﬁc knockout of the PPAR-
γ receptor, suggesting that this drug has some additional
indirect eﬀects to induce hypertrophy [2]. In the present
study, plasma-volume expansion induced cardiac volume
overload could be one such indirect mechanism for cardiac
remodeling in PD168-treated rats. This is supported by the
observation that the fall in hematocrit presented from day 7
onward, preceded changes in cardiac structure or function
as assessed by echocardiography. Furthermore our previous
short-term study with PD-168 at 10mg/kg in SD rats clearly
demonstrated that the fall in hematocrit started from day
1 of the treatment [21]. Furthermore, activation of the
renin-angiotensin-aldosterone system (RAAS), as suggested
by increased aldosterone excretion by PPAR-γ agonists could
also contribute to hypertrophy and remodeling of the heart
[46–48].
Nevertheless, there are some studies which support a
direct eﬀect of PPAR-γagonists via PPAR-γreceptors on the
heart producing detrimental eﬀects on cardiac structure
and function. In this regard, over-expression of PPAR-γ
in the heart resulted in cardiac dysfunction [49]. Thus,
cardiac dysfunction as indicated by reduced ejection fraction
and left ventricular hypertrophy in our study may be the
result of cardiac-speciﬁc eﬀects of these agents. In contrast,
there are some studies which suggest a protective eﬀect of
PPAR-γ agonists with regard to cardiac hypertrophy and
heart function [50–52]. Despite data from various studies
in diseased or non-diseased models, it is still controversial
whether agonists of PPAR-γ have beneﬁcial or deleterious
eﬀects on the heart.
Higher circulating levels of adiponectin are related to a
reduced risk of cardiovascular disease in healthy individuals
[53, 54]. Our ﬁnding of elevated plasma adiponectin along
with cardiac dysfunction in PD168 treated rats counters
these anti-inﬂammatory and anti-atherogenic properties
of adiponectin. However, we do not believe that higher
adiponectin level has any causative role in cardiac dysfunc-
tion found in this study. We believe that elevated plasma
adiponectin levels and cardiac dysfunction are two inde-
pendent eﬀects of PPAR-γ agonists observed in our study.
Nonetheless, some epidemiologic studies have reported
that high adiponectin levels were associated with increased
cardiovascular mortality in patients with chronic kidney
disease, chronic heart failure and hemodialysis patients
with type 2 diabetes mellitus [55–57]. Furthermore, it has
been suggested that hypervolemic conditions in patient
populations may modulate the eﬀect of plasma adiponectin
levels [57]. Thus, it is possible that the cardioprotective
actionofelevatedadiponectinlevelsisdisruptedbyincreased
plasma volume found in PD168 treated rats in our study.
In summary, results from the present study suggest that
chronic treatment with a potent PPAR-γ agonist may intro-
duce a risk factor for a sequel of events that may precipitate
the eventual development of left ventricular dysfunction and
CHFeveninanotherwisehealthyheart.Edemacoupledwith
eccentric hypertrophy suggests volume overload to be one
possible mechanism. Like normal rats in our study, most
patients with no cardiovascular impairment can tolerate
modest increases in intravascular volume; however, patients
with impaired cardiovascular reserve or risk factors for
cardiac dysfunction may manifest CHF signs and symptoms
in the setting of this magnitude of volume expansion.
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